Adalvo announces the successful DCP submission for Empagliflozin/Metformin film-coated tablets, with an anticipated approval date in June 2025.
Developed based on the reference brand Synjardy film-coated tablets, Empagliflozin/Metformin is indicated for the treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
Empagliflozin/Metformin sold approximately $1035Mn globally in 2023, with a global 3Y CAGR of +15%, according to IQVIA.
Based on the timing of this submission and our IP strategy, Adalvo expects to be among the first companies to launch on Day-1, in all major markets.
The successful development of this product highlights Adalvo's ability to offer our partners difficult-to-make, high-value differentiated products.
Adalvo has developed one of the broadest diabetes pipelines in the industry with an extensive range of therapeutic options. Our diverse portfolio includes small molecules and peptide-based treatments, encompassing both oral and parenteral formulations, from short to long-acting range. This comprehensive approach makes diabetes care more manageable for patients worldwide.
There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!